Skip to main content

letter

. 1978 Oct 21;2(6145):1161. doi: 10.1136/bmj.2.6145.1161

Razoxane in treatment of acute myeloid leukaemia.

PMCID: PMC1608210 PMID: 280402

1161

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bhavnani M., Dhir K., Delamore I. W. Razoxane in treatment of acute myeloid leukaemia. Br Med J. 1978 Sep 16;2(6140):801–801. doi: 10.1136/bmj.2.6140.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
Grieder A., Maurer R., Stähelin H. Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer Res. 1977 Sep;37(9):2998–3005. [PubMed] [Google Scholar]
Hallowes R. C., West D. G., Hellmann K. Cumulative cytostatic effect of ICRF 159. Nature. 1974 Feb 15;247(5441):487–490. doi: 10.1038/247487a0. [DOI] [PubMed] [Google Scholar]
Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES